FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2068795972> ?p ?o ?g. }

• W2068795972 endingPage "1139" @default.
• W2068795972 startingPage "1132" @default.
• W2068795972 abstract "Nonmyeloablative allogeneic transplantation (NMAT) infrequently cures active chemoresistant, bulky, or aggressive B-cell lymphoma (B-cell non-Hodgkin lymphoma [B-NHL]). We hypothesized that ⁹⁰Y-ibritumomab tiuxetan-based NMAT would facilitate early cytoreduction in such patients promoting improved long-term disease control by the allogeneic graft. Forty high-risk B-NHL patients with persistent disease received 0.4 mCi/kg (maximum, 32 mCi/kg) ⁹⁰Y-ibritumomab tiuxetan, fludarabine, and 2 Gy total body irradiation and matched-related (15) or unrelated (25) transplantation. Baseline features included: median age, 58 years (range, 29-69 years); median prior regimens, 6 (range, 3-12); chemosensitive disease, 6 (15%); bulk > 5 cm, 17 (range, 5.2-18.6 cm, 43%); diffuse large B-cell lymphoma, 14 (35%); and comorbidity score > zero, 34 (85%). Early responses were observed in 24 (60%, 14 complete remission/complete remission unconfirmed, 10 partial response) patients, including 17 of 29 (59%) with chemotherapy-resistant disease and 10 (59%) with bulk > 5 cm. The estimated 30-month survival, progression-free survival, and nonrelapse mortality were 54.1%, 31.1%, and 15.9%, respectively. Early response, baseline platelet counts over 25 000/μL, indolent histology, and related donors were associated with improved survival. The addition of ⁹⁰Y-ibritumomab tiuxetan to NMAT is safe and yields early responses and prolonged disease control in some of the highest-risk B-NHL patients. This trial was registered at www.clinicaltrials.gov as #NCT00119392." @default.
• W2068795972 created "2016-06-24" @default.
• W2068795972 creator A5004025497 @default.
• W2068795972 creator A5004610095 @default.
• W2068795972 creator A5016684714 @default.
• W2068795972 creator A5040412322 @default.
• W2068795972 creator A5048654505 @default.
• W2068795972 creator A5061049816 @default.
• W2068795972 creator A5078791373 @default.
• W2068795972 creator A5085460280 @default.
• W2068795972 creator A5085787488 @default.
• W2068795972 date "2011-07-28" @default.
• W2068795972 modified "2023-10-02" @default.
• W2068795972 title "90Y-Ibritumomab tiuxetan, fludarabine, and TBI-based nonmyeloablative allogeneic transplantation conditioning for patients with persistent high-risk B-cell lymphoma" @default.
• W2068795972 cites W107716097 @default.
• W2068795972 cites W1912693401 @default.
• W2068795972 cites W1978659582 @default.
• W2068795972 cites W1989425120 @default.
• W2068795972 cites W1992558210 @default.
• W2068795972 cites W1998627443 @default.
• W2068795972 cites W2009962661 @default.
• W2068795972 cites W2014654561 @default.
• W2068795972 cites W2019131761 @default.
• W2068795972 cites W2020214604 @default.
• W2068795972 cites W2020764618 @default.
• W2068795972 cites W2033761235 @default.
• W2068795972 cites W2035841279 @default.
• W2068795972 cites W2041925366 @default.
• W2068795972 cites W2045209749 @default.
• W2068795972 cites W2047164612 @default.
• W2068795972 cites W2052275340 @default.
• W2068795972 cites W2054823183 @default.
• W2068795972 cites W2058887761 @default.
• W2068795972 cites W2069441856 @default.
• W2068795972 cites W2078782557 @default.
• W2068795972 cites W2097470232 @default.
• W2068795972 cites W2103255742 @default.
• W2068795972 cites W2117034501 @default.
• W2068795972 cites W2128812336 @default.
• W2068795972 cites W2132678616 @default.
• W2068795972 cites W2147581636 @default.
• W2068795972 cites W2149156161 @default.
• W2068795972 cites W2152911354 @default.
• W2068795972 cites W2159608407 @default.
• W2068795972 cites W2160885679 @default.
• W2068795972 cites W2320751441 @default.
• W2068795972 doi "https://doi.org/10.1182/blood-2010-12-324392" @default.
• W2068795972 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3673760" @default.
• W2068795972 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21508413" @default.
• W2068795972 hasPublicationYear "2011" @default.
• W2068795972 type Work @default.
• W2068795972 sameAs 2068795972 @default.
• W2068795972 citedByCount "63" @default.
• W2068795972 countsByYear W20687959722012 @default.
• W2068795972 countsByYear W20687959722013 @default.
• W2068795972 countsByYear W20687959722014 @default.
• W2068795972 countsByYear W20687959722015 @default.
• W2068795972 countsByYear W20687959722016 @default.
• W2068795972 countsByYear W20687959722017 @default.
• W2068795972 countsByYear W20687959722018 @default.
• W2068795972 countsByYear W20687959722019 @default.
• W2068795972 countsByYear W20687959722020 @default.
• W2068795972 countsByYear W20687959722021 @default.
• W2068795972 countsByYear W20687959722022 @default.
• W2068795972 countsByYear W20687959722023 @default.
• W2068795972 crossrefType "journal-article" @default.
• W2068795972 hasAuthorship W2068795972A5004025497 @default.
• W2068795972 hasAuthorship W2068795972A5004610095 @default.
• W2068795972 hasAuthorship W2068795972A5016684714 @default.
• W2068795972 hasAuthorship W2068795972A5040412322 @default.
• W2068795972 hasAuthorship W2068795972A5048654505 @default.
• W2068795972 hasAuthorship W2068795972A5061049816 @default.
• W2068795972 hasAuthorship W2068795972A5078791373 @default.
• W2068795972 hasAuthorship W2068795972A5085460280 @default.
• W2068795972 hasAuthorship W2068795972A5085787488 @default.
• W2068795972 hasBestOaLocation W20687959721 @default.
• W2068795972 hasConcept C126322002 @default.
• W2068795972 hasConcept C141071460 @default.
• W2068795972 hasConcept C143998085 @default.
• W2068795972 hasConcept C159654299 @default.
• W2068795972 hasConcept C203014093 @default.
• W2068795972 hasConcept C2776146153 @default.
• W2068795972 hasConcept C2776694085 @default.
• W2068795972 hasConcept C2776755627 @default.
• W2068795972 hasConcept C2778515704 @default.
• W2068795972 hasConcept C2778559949 @default.
• W2068795972 hasConcept C2778880498 @default.
• W2068795972 hasConcept C2779263901 @default.
• W2068795972 hasConcept C2779338263 @default.
• W2068795972 hasConcept C2911091166 @default.
• W2068795972 hasConcept C542903549 @default.
• W2068795972 hasConcept C71924100 @default.
• W2068795972 hasConcept C90924648 @default.
• W2068795972 hasConceptScore W2068795972C126322002 @default.
• W2068795972 hasConceptScore W2068795972C141071460 @default.
• W2068795972 hasConceptScore W2068795972C143998085 @default.
• W2068795972 hasConceptScore W2068795972C159654299 @default.
• W2068795972 hasConceptScore W2068795972C203014093 @default.

• next